Simultaneously, the combination regimen of LTX/siR‐NPs with anti‐NKG2A antibody exhibits a superior potency in enhancing NK and CD8+ T cells' cytotoxic function against the tumor cells, and as a result, inhibits the tumor growth and prolongs the survival rate of treated mice. This evidence concerns the gene CD8A and neoplasm.